Asthma is a chronic lung disease affecting millions worldwide. While classically
acknowledged to result from allergen-driven type 2 inflammatory responses leading to IgE …

Inhaled therapeutics are used routinely to treat a variety of pulmonary diseases including
asthma, COPD and cystic fibrosis. In addition, biological therapies represent the fastest …

Despite remarkable advances in diagnosis and long-term management, asthma remains a
serious public health concern. Newly updated expert guidelines emphasize the intra-and …

Asthma is one of the leading causes of mortality worldwide presenting a huge socio-
economic burden with rising morbidity and mortality rates. It is a chronic inflammatory airway …

Introduction Advances in understanding the pathophysiology of asthma and chronic
obstructive pulmonary disease (COPD) led to investigation of biologic drugs targeting …

Abstract Globally, a small proportion (5–12%) of asthma patients are estimated to have
severe disease. However, severe asthma accounts for disproportionately high healthcare …

Until the late 1990s, aerosol therapy consisted of beta 2-adrenergic agonists, anti-
cholinergics, steroidal and non-steroidal agents, mucolytics and antibiotics that were used to …

Airway mucus hypersecretion is a pathophysiological feature of asthma and chronic
obstructive pulmonary disease (COPD). The hypersecretion is associated with phenotypic …

Aerosolized medications have been used for centuries to treat respiratory diseases. Until
recently, inhalation therapy focused primarily on the treatment of asthma and chronic …

Asthma is a chronic respiratory disorder canonically associated with type 2 airway
inflammation as characterized by elevated levels of eosinophils, immunoglobulin E, and …